Nature Communications (Jan 2020)
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
- Timothy P. Sheahan,
- Amy C. Sims,
- Sarah R. Leist,
- Alexandra Schäfer,
- John Won,
- Ariane J. Brown,
- Stephanie A. Montgomery,
- Alison Hogg,
- Darius Babusis,
- Michael O. Clarke,
- Jamie E. Spahn,
- Laura Bauer,
- Scott Sellers,
- Danielle Porter,
- Joy Y. Feng,
- Tomas Cihlar,
- Robert Jordan,
- Mark R. Denison,
- Ralph S. Baric
Affiliations
- Timothy P. Sheahan
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Amy C. Sims
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Sarah R. Leist
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Alexandra Schäfer
- Department of Epidemiology, University of North Carolina at Chapel Hill
- John Won
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Ariane J. Brown
- Department of Epidemiology, University of North Carolina at Chapel Hill
- Stephanie A. Montgomery
- Department of Pathology & Laboratory Medicine, University of North Carolina
- Alison Hogg
- Gilead Sciences, Inc
- Darius Babusis
- Gilead Sciences, Inc
- Michael O. Clarke
- Gilead Sciences, Inc
- Jamie E. Spahn
- Gilead Sciences, Inc
- Laura Bauer
- Gilead Sciences, Inc
- Scott Sellers
- Gilead Sciences, Inc
- Danielle Porter
- Gilead Sciences, Inc
- Joy Y. Feng
- Gilead Sciences, Inc
- Tomas Cihlar
- Gilead Sciences, Inc
- Robert Jordan
- Gilead Sciences, Inc
- Mark R. Denison
- Department of Pediatrics-Infectious Diseases, Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center
- Ralph S. Baric
- Department of Epidemiology, University of North Carolina at Chapel Hill
- DOI
- https://doi.org/10.1038/s41467-019-13940-6
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Remdesivir (RDV) is a broad-spectrum antiviral drug with activity against MERS coronavirus, but in vivo efficacy has not been evaluated. Here, the authors show that RDV has superior anti-MERS activity in vitro and in vivo compared to combination therapy with lopinavir, ritonavir and interferon beta and reduces severe lung pathology.
